JNJ Johnson & Johnson Common Stock

127.52
+0.26  (0%)
Previous Close 127.26
Open 127.31
Price To book 4.88
Market Cap 343.52B
Shares 2,693,833,000
Volume 3,972,921
Short Ratio 2.31
Av. Daily Volume 6,307,180

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Cardiovascular Outcomes trial data due June 12, 2017 at American Diabetes Association meeting.
INVOKANA CANVAS
Type 2 diabetes
Phase 3 trial to be completed in 2018.
STELARA (USTEKINUMAB)
Ulcerative colitis
Primary endpoint of non inferiority met - December 19, 2016.
Rilpivirine and Dolutegravir
HIV
Phase 3 data due 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Phase 3 data likely due 2019.
DARZALEX (Daratumumab)
Frontline multiple myeloma (transplant)
Phase 3 data likely due 2018.
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further review conducted April 2017 - further development pending FDA feedback and longer term data.
Imetelstat - IMbarkStudy
Myelofibrosis
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal reviews conducted September 2016 and April 2017, trial to continue as planned. Phase 3 part of trial to be initiated 4Q 2017 pending FDA feedback.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 3 ongoing. Data and regulatory filings likely due 2018.
Esketamine
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
sBLA filing announced December 15, 2016. PDUFA estimate October 15, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
BLA submission announced November 17, 2016. PDUFA date estimate November 17, 2017.
Guselkumab
Plaque psoriasis
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
Sirukumab
Rheumatoid arthritis
PDUFA date June 17, 2017
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma

Latest News

  1. 3 Top Dividend Stocks in the Dentistry Industry
  2. Alexion’s top management shake-up includes CFO who started in December
  3. Here's Why Alexion Pharma (ALXN) Stock is Sinking Today
  4. Alexion stock plummets 9% after top management shake-up
  5. Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17
  6. 3 Stocks to Add to Your Social Security Income
  7. The 3 Best Dividend Stocks in Arthritis Medication
  8. These 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop?
  9. 3 Ways Johnson & Johnson's Pharmaceutical Business Plans to Beat the Market
  10. 5 Entrepreneur Ideas From Tremendously Innovative Companies
  11. Dow 30 Stock Roundup: Home Depot, Cisco, Wal-Mart Beat on Earnings
  12. Johnson & Johnson Unit Sues to Block Sale of Copy of its Rheumatoid Arthritis Drug
  13. Why Is Johnson & Johnson (JNJ) Up 4.4% Since the Last Earnings Report?
  14. Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy
  15. Ortho-Clinical Diagnostics SA -- Moody's assigns B1 to Ortho-Clinical's proposed senior secured revolving credit facility
  16. Why Achillion Pharmaceuticals Stock Is Jumping 15% Today
  17. Why ImmunoGen, Inc. Jumped Higher Today
  18. Understanding J&J's Risk From New FDA Label Warning For Invokana
  19. 3 Warren Buffett Stocks for Senior Citizens
  20. Achillion: It Can't Get Any Worse…Or Can It?